**Supplementary Table 3**

**Factors associated with non-regression of liver fibrosis stage after direct-acting antiviral agent therapy between end of treatment and SVR96**

|  |  |  |  |
| --- | --- | --- | --- |
| At EOT | **Regression** | **Non-regression** | **P value** |
| **Number** | **19** | **3** |  |
| Age (years)a | 64(44-81) | 69(56-71) | 0.787 |
| Sex (male/female) | 7/12 | 1/2 | 0.709 |
| HCV-RNA (log IU/mL) a | 0 | 0 |  |
| DCV/ASV,　SOF/LDV,　 SOF/RBV, 　OBV/PTV/r | 5/7/6/1 | 0/1/2/0 | 0.608 |
| F0-2/3-4 | 15/4 | 0/3 | \*0.023 |
| Platelet count (×104) a | 17.2(5.4-28) | 8.4(4.8-19.6) | 0.191 |
| AST (IU/L) a | 23(16-39 | 27(25-74) | 0.087 |
| ALT (IU/L) a | 17(5-31) | 24(9-71) | 0.464 |
| FIB-4 index a | 2.15(0.81-4.99) | 7.21(2-9.72) | 0.087 |
| Angiopoietin-2 (pg/mL) a | 266.7(139.8-543.8) | 579.3(416.6-913) | \*0.005 |
| CAP (dB/m) a | 211(102-386) | 210(100-235) | 0.857 |
| Spleen index (cm2) a | 27.3(13-56.5) | 30.7(30.7-47.1) | 0.254 |

Abbreviations: HCV, Hepatitis C virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; FIB-4, fibrosis 4; CAP, Controlled Attenuation Parameter.

a Data are shown as median (range) values. \*Statistically significant difference, P <0.05.